Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Phase 1 Completed 34 enrolled Shionogi

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and pharmacokinetics of double-blind S-707106 alone and in combination with open-label metformin in patients with type 2 diabetes mellitus

Timeline

Start: 2010-06
Primary completion: 2010-11
Completion: 2010-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	S-707106	Unknown	—	—
Background	Metformin	Small molecule	—	—

Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus

Summary

Timeline

Drugs

Indications